Tick-borne infections (TBIs) are caused by a variety of bacterial, viral, and parasitic pathogens whose incidence varies across different regions of the United States.
babesiosis includes thick and thin blood smear, serology, and PCR. Tests for anaplasmosis include serology and PCR. The availability of some of these tests has changed over time as reference laboratories have continually expanded their test offerings. In addition, tests for more recently identified TBI in North America, such as B miyamotoi infection, have become available. For these reasons, the menu of available clinical laboratory tests has evolved over the past decade, reflecting the development of new testing modalities and the introduction of tests for newly identified pathogens.
The Massachusetts General Hospital (MGH) is a large tertiary care academic medical center in Boston, Massachusetts, serving Boston and surrounding communities. Given its geographical location, a large number of patients with possible TBI are evaluated at the MGH. The clinical laboratories at the MGH provide testing in support of clinical care throughout the hospital and outpatient practices, including testing for TBI. Given the increased frequency of TBI reported both regionally and nationally, and the emergence of newly recognized TBI, the volume and complexity of testing for these infections would be expected to be increasing. In this study, we report an 11-year analysis of testing patterns for TBI in our hospital, including testing volumes, rates of positivity, and the changing patterns of testing modalities over time.
Materials and Methods
This retrospective study was approved by the Partners HealthCare Institutional Review Board.
Site
The MGH is a 999 bed academic medical center located in downtown Boston, Massachusetts. The MGH is a member of the Partners HealthCare System and a teaching affiliate of Harvard Medical School. The hospital provides comprehensive medical services, including primary care to the region, admitting approximately 48,000 patients, delivering nearly 1.5 million outpatient visits per year, and over 100,000 emergency department visits. This includes care for tick-borne diseases endemic to the New England region.
Data Collection
Using our laboratory information system (Sunquest Information Systems, Tucson, AZ) we identified 29 laboratory test codes used to assess tick-borne diseases, including borreliosis, babesiosis, anaplasmosis, and ehrlichiosis. We then extracted clinical laboratory result data spanning 11 years (January 1, 2006 to December 31, 2016) for these codes from our information system.
Data Analysis
Data analysis and visualization were performed in the Python programming language as implemented in the Anaconda package (Python 3.5.1 in Anaconda 2.4.1 [32-bit]; Continuum Analytics, Austin, TX). Test volumes and results were obtained from our laboratory information system (Sunquest).
Results for 0.14% of the test results did not contain adequate result information to determine positivity, and these results were excluded from the analysis. The test performance volumes for babesiosis evaluation by thick and thin smear also includes requests for malaria smear evaluation. Thick and thin smear is our test of choice for the assessment of both organisms and the result data did not reliably allow us to differentiate the specific indication for the test request. However, the positive smear results are specific to Babesia, as the result data allow for discrimination between positive malaria and Babesia results. Result classification for Babesia serology was determined by manual review given the small number of test requests, and variation in result reporting. Ehrlichiosis and anaplasmosis were classified together, as they are frequently included in the same test batteries and evaluated in tandem.
We also assessed limited demographic data available to us with the laboratory results, including sex, age, and the context in which the order was placed (inpatient, outpatient, emergency department). Age could not be determined in a small subset of batteries (264/76,645, 0.3% of results).
Data Visualization
We created visualizations for the results in Python using the Matplotlib package (version 1.5.0), which is included in Anaconda.
Results

Patient Demographics
Patients ranged in age from 2 to 102 years old with a median age of 50 years. The 25th and 75th percentiles were 35 and 62 years, respectively. Slightly more than half the battery results were attributable to female patients (53.5% female, 46.4% male, 0.1% unknown). The vast majority of orders were reported in patients from the outpatient setting (76%), followed by inpatient locations (20.4%), and the emergency department (3.5%).
Overall Trends in Tick-Borne Disease Test Volumes
We identified 76,755 unique tick-borne battery results. After excluding two batteries for which the result data did not allow for positivity evaluation as described in the "Materials and Methods" section (110 results, 0.14% of total extracted data), 76,645 battery results remained. Of the remaining results, we classified 73,642 battery results as positive or negative. This represents 96% of the original data extraction (73,642/76,755) and comprised our final data set. The remaining 4% of data included battery requests not performed and those unable to be classified by our rule sets as described in the "Materials and Methods." Aggregated data for test positivity and volumes by method are shown in ❚Table 1❚. Overall, between 2006 and 2016, the total test volume for TBI increased from 1,720 to 9,171 (5.3-fold) with a peak of 10,172 in 2013 (5.9-fold). Test volumes for all TBI showed significant increases during the study period. Testing for Lyme disease comprised 75.6% of the total TBI testing volume over the study period followed by Babesia (12.3%), Anaplasma/ Ehrlichia (11.0%), and B miyamotoi (0.8%).
Total DNA PCR testing is a rarely used assay for Lyme disease in our institution.
Other Tick-Borne Disease Test Volumes
Test volumes for babesiosis (and malaria) have increased over the last decade ❚Figure 3A❚. Our preferred method for the assessment of babesiosis since 2014 is microscopic examination of thick and thin smears. As described in the "Materials and Methods," thick and thin smear is the test of choice for babesiosis in our institution but the examination can also detect malaria. As such, the smear volumes represent requests for either malaria or babesiosis evaluation. We have approximately twice as many babesiosis identifications as malaria identifications by thick and thin smear over the last 10 years. Malaria identifications are not included in the tables or figures. We identified a range from 13 positive cases of babesiosis by smear examination (2008) to 102 cases (2013) (7.7-fold increase), followed by a decline in 2014 to 2016. The decline in Babesia serology requests corresponds to a discontinuation of that method in our institution in 2014 as part of a utilization management initiative. In addition, only rarely were acute and convalescent-phase sera obtained in the same patient.
Requests for Ehrlichia and Anaplasma testing have risen dramatically at our institution over the past 10 years, from less than 200 tests performed per year prior to 2007 to nearly 1,600 per year in 2013 ❚Figure 3B❚ (Table 1) . Serology and molecular methods were often ordered together, and in 2014 we began restricting serologic testing in favor of PCR to avoid duplicative orders. We also observed that acute-and convalescent-phase titers were only rarely obtained in the same patient.
B miyamotoi infection is a newly identified tick-borne illness in North America, and testing has increased since this became available in 2013 ❚Figure 3C❚. To date, we have documented fewer than 50 positive test results by serologic (IgM or IgG) or molecular methods. The absolute number of positive cases is increasing year on year.
❚Figure 3D❚ shows a composite of all non-Lyme positive test results. The annual number of positive tests has increased over the years with a peak in 2013 (similar to Lyme disease data).
Discussion
In this study, we report trends in testing for TBI in our institution over an 11-year period. The data presented only reflect the known TBI that are endemic to our region in the northeastern United States. Overall, the trends show increasing requests for TBI testing with an increase in the number of positive results for all TBI pathogens endemic to our region. These results may reflect an absolute increase in the incidence of TBI in our patient population and/or may reflect increased awareness of these infections among the medical community and the public. There was a modest decline in the volume of TBI tests in 2014 to 2016. There are many possible explanations for this, including greater awareness of tick preventative measures and possibly seasonal climatic factors that influence the abundance of ticks 6 or populations of white-footed mice in the community. 7 As our data demonstrate, laboratory testing detected an especially high number of TBI at our hospital in 2013, which may have led to increased awareness among health care providers, leading to higher levels of test requests that were not sustained in subsequent years.
In the case of Lyme disease specifically, serologic tests increased 12. tests for new tick-borne pathogens have become available (eg, B miyamotoi). Other TBI continue to be discovered, albeit we have not observed any testing yet in our institution (eg, Borrelia mayonii). 8 We did not include data for tularemia, as this is relatively rare.
9
In recent years, we implemented two utilization management initiatives in collaboration with the Division of Infectious Diseases, including discontinuation of Babesia serology in favor of thick and thin smears (often both tests were ordered, and only rarely were acute and convalescent sera obtained) and restriction of Anaplasma/Ehrlichia serologic testing in favor of PCR (again both tests were often ordered). In both cases we observed that only rarely were acute-and convalescent-phase sera obtained in the same patient. Because there were many duplicative orders, the test volumes for these pathogens prior to our utilization management initiatives are skewed higher than the actual number of individual patients tested.
Testing for babesiosis more than doubled over the study period, with an increase in the number of patients testing positive. The number of positive smears varied from a low of 13 in 2008 to a high of 102 in 2013 (7.8-fold difference).
Excluding serology, testing for Anaplasma phagocytophilum/Ehrlichia species by PCR showed a large increase, from 24 tests in 2006 to 910 tests in 2016 (37.9-fold increase). The annual number of positive test results went from 0 to 24. The overwhelming majority of these cases were Anaplasma, as we rarely see Ehrlichia infection in Eastern Massachusetts. B miyamotoi was previously described in ticks in Japan, and the first case of a B miyamotoi TBI in North America was reported in 2012. 10 Both PCR and serologic methods are available. Although testing for this infection remains relatively uncommon, we have observed a number of patients with positive test results, particularly by serology. Most patients with acute symptomatic B miyamotoi infection are seronegative, 11 and a positive serology without acute-and convalescent-phase specimens is difficult to interpret. In acute infection, PCR is the preferred test. 11 This suggests another potential utilization management opportunity in our institution.
Several limitations to our study should be noted. First, some of the changes in testing patterns over time could potentially be explained by an evolution in our patient population over time and by changes in the physician composition of our practice organization. Second, for many pathogens the presence of a positive test does not always indicate a current infection, and a negative result does not always exclude infection in individual cases. For example, many patients with early Lyme disease are seronegative and some patients with clinically evident Lyme disease may not be tested. Babesia cases with very low organism burden may be missed on thick and thin smear. Despite these limitations, our results demonstrate a significant increase in testing for TBI in our institution and the number of cases appears to be increasing over time, with seasonal variation from year to year. 
